Aravive Inc (ARAV)
US03890D1081 - Common Stock
ARAV gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of ARAV is average, but there are quite some concerns on its profitability. ARAV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year ARAV has reported negative net income.
ARAV had a negative operating cash flow in the past year.
ARAV had negative earnings in each of the past 5 years.
ARAV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ARAV (-306.54%) is worse than 96.29% of its industry peers.
ARAV has a Return On Equity of -2344.12%. This is amonst the worse of the industry: ARAV underperforms 86.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| ROIC | N/A |
ROA(3y)-75.18%
ROA(5y)-71.51%
ROE(3y)-289.85%
ROE(5y)-204.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARAV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARAV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ARAV has been increased compared to 1 year ago.
The number of shares outstanding for ARAV has been increased compared to 5 years ago.
There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ARAV has an Altman-Z score of -81.87. This is a bad value and indicates that ARAV is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ARAV (-81.87) is worse than 98.99% of its industry peers.
There is no outstanding debt for ARAV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -81.87 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
A Current Ratio of 0.98 indicates that ARAV may have some problems paying its short term obligations.
The Current ratio of ARAV (0.98) is worse than 90.56% of its industry peers.
ARAV has a Quick Ratio of 0.98. This is a bad value and indicates that ARAV is not financially healthy enough and could expect problems in meeting its short term obligations.
ARAV's Quick ratio of 0.98 is on the low side compared to the rest of the industry. ARAV is outperformed by 89.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 |
3. Growth
3.1 Past
ARAV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.32%, which is quite impressive.
The Revenue for ARAV has decreased by -19.28% in the past year. This is quite bad
The Revenue for ARAV have been decreasing by -25.56% on average. This is quite bad
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q154.9%
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y-25.56%
Revenue growth Q2Q-44.35%
3.2 Future
ARAV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.50% yearly.
Based on estimates for the next years, ARAV will show a very negative growth in Revenue. The Revenue will decrease by -21.62% on average per year.
EPS Next Y90.73%
EPS Next 2Y39.94%
EPS Next 3Y25.99%
EPS Next 5Y10.5%
Revenue Next Year-38.62%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-21.62%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ARAV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ARAV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ARAV's earnings are expected to grow with 25.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.94%
EPS Next 3Y25.99%
5. Dividend
5.1 Amount
No dividends for ARAV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Aravive Inc
NASDAQ:ARAV (1/26/2024, 7:02:10 PM)
After market: 0.042 +0 (+4.74%)0.0401
-0.01 (-13.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.95M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -306.54% | ||
| ROE | -2344.12% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.98 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)59.32%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y90.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-19.28%
Revenue growth 3Y24.38%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y